From November 14 to 18, 2023, the 50th VEITH Symposium (VEITH 2023) was held in New York, USA. Professor Lu Shaoying from the First Affiliated Hospital (FAH) of Xi'an Jiaotong University (XJTU) was invited to attend and deliver a keynote speech regarding percutaneous embolization of congenital cervical arteriovenous fistula with AVPs device. Congenital arteriovenous fistula in the neck is a rare disease. Due to large number of supplying arteries and varying number of malformed vascular clusters, it is difficult to achieve radical treatment with embolization, and recurrence is likely to occur after surgical resection. Therefore, how to further optimize the treatment strategy has become a major challenge in clinical practice. Director Lu Shaoying reported that AVPs device exerted favorable embolization effect in the treatment of congenital arteriovenous fistula in the neck, which acted as a safe and efficacious option and also provided a novel therapeutic possibility for such disease.
Recommended by Wayne W. Zhang, a prestigious ethnic Chinese vascular surgeon from Washington in USA, Professor Lu Shaoying was invited by Matt Eagleton, an internationally-renowned vascular surgeon from Harvard University to visit Massachusetts General Hospital of Harvard University and delivered a report regarding an engineering medicine project of the FAH entitled Application prospect of OCT in lower extremity artery diseases. His research achievements received recognition from colleagues and peers at Harvard University. Department of Vascular Surgery of our hospital and the team from VIVOLIGHT are jointly assessing the potential of OCT laser imaging technology as a novel technology to evaluate the severity of lower limb artery disease. OCT technology has been widely applied in coronary artery disease, whereas it has been rarely reported in lower limb artery disease worldwide. Consequently, the hospital has reached the advanced levels in this field.
